

**STEP 1:**

The patient expresses interest with the clinician.



1

**STEP 3:**

Arrange a detailed counseling session with the care team and discuss the following:

- a. The process to obtain the medication
- b. Patient benefits discussion
- c. Optional CAB/RPV lead-in dosing
- d. Injection window
- e. Expectations
- f. Side Effects
- g. Adherence
- h. Discuss Patient questions/concerns
- i. Pregnancy counseling
- j. Remind patient they must alert the team of any changes in coverage (gain/loss) while prescribed Cabenuva
- k. Educate about EOB statements from private insurance necessary to submit for ViiV Patient Savings Program


3

**STEP 2:**

Discuss and assess the patient's qualifications/appropriateness of therapy and pre-screen testing.

- a. Amenable to 2 gluteal injections at monthly or every 2 month appointments
- b. Has a suppressed VL (VL < 50 copies/mL) for at least 3 months
- c. Lacks drug resistance mutations to cabotegravir/rilpivirine
- d. Lacks any drug interactions w/ cabotegravir/rilpivirine (eg. PPIs with oral rilpivirine)

- e. Lacks any contraindications to therapy
- f. Lacks HBV coinfection or willing to start alternative hepatitis B treatment
  - i. Must screen for HBV before starting
  - ii. Risk of HBV immune reconstitution inflammatory syndrome or HBV reactivation
- g. Is not pregnant



**STEP 4:**

**Enroll the patient in ViiVConnect.**

- a. Assign team member to keep track of PA expiration/benefit approval dates
- b. Coordinate with the specialty pharmacy (SP) or specialty distributor (SD), according to each patient's insurance requirements

**STEP 5:**

**Order the optional oral lead-in medication to be delivered to the patient (Oral)**

- a. Oral lead-in of CAB 30 mg plus RPV 25 mg once daily with food for at least 28 days
- b. Order by contacting TheraCom via phone (844-276-6299), fax (833-904-1881), or ePrescribe

5

6

**STEP 6:**

**Order the injectable medication to be delivered to the clinic (LAA)**

- a. Schedule/confirm 1st injection visit on receipt of medication
  1. Schedule first IM injection visit (day 28-30 of optional oral lead-in phase) for at least 60 minutes
- b. Clinic Storage:
  - i. Store medication in refrigerator
  - ii. Document on Cabotegravir/rilpivirine storage log:
    1. Date/time received
    2. Person accepting
    3. Patient name
    4. Date/time dispensed
    5. Person dispensing

4



7

..... **STEP 7: First Injection Visit (60 min)**

- a. Loading dose is CAB 600 mg (3 mL) and RPV 900 mg (3 mL) (day 28-30 of optional oral lead-in)
  - i. Given as two separate injections in separate ventrogluteal sites
- b. **RN to take medication out of the fridge when the patient arrives and allow 15 minutes to come to room temperature.**
- c. Unopened kit should be labeled with time it was removed from fridge
  - i. The vials may remain in the carton at room temperature for up to 6 hours.

- ii. Medication must be discarded if not used within 6 hours
- d. Administer CAB and RPV at separate gluteal injection sites (on opposite sides or 2 cm apart)
  - i. Use of longer 2-inch needle for BMI  $\geq 30$  kg/m<sup>2</sup> recommended
- e. Allow 10 to 15 minutes to monitor for adverse effects post-injection
- f. RN to chart against order that Cabenuva dose was given and then document visit
- g. Schedule second injection one month later (+/- 7 day window) from 1st injection

8

**STEP 8:**

**Second Injection Visit (30min)**

- a. Dosing:
  - i. Continuation therapy with monthly CAB 400 mg (2 mL) and RPV 600 mg (2 mL); or
  - ii. Every-2-Month Dosing CAB 600 mg (3 mL) and RPV 900 mg (3 mL)
    - l. Given as two separate ventrogluteal IM injections
- b. **RN to remove medication from refrigerator when the patient arrives and allow 15 minutes to come to room temperature.**
- c. Unopened kit should be labeled with time it was removed from fridge
  - i. The vials may remain in the carton at room temperature for up to 6 hours.
  - ii. Medication must be discarded if not used within 6 hours
- d. Schedule follow up in one month for 400/600 mg dosing or 2 months for 600/900 mg dosing



